Stability of tacrolimus ophthalmic solution

被引:13
|
作者
Ezquer-Garin, Carlos [1 ,2 ]
Ferriols-Lisart, Rafael [3 ,4 ]
Alos-Alminana, Manuel [1 ,4 ]
机构
[1] Univ Valencia, INCLIVA, Inst Hlth Res, Valencia, Spain
[2] Univ Valencia, Hosp Clin, Valencia, Spain
[3] Univ Valencia, Inst Hlth Res, INCLIVA, Clin Pharmacokinet Lab, Valencia, Spain
[4] Univ Valencia, Hosp Clin, Dept Pharm, Valencia, Spain
关键词
drug stability; ophthalmic solutions; tacrolimus; HUMAN LIVER-MICROSOMES; VERSUS-HOST-DISEASE; CYCLOSPORINE-A; EYE DROPS; DRY EYE; TRANSPLANTATION; FK506; METABOLISM; IMMUNOSUPPRESSION; COMPLEX;
D O I
10.2146/ajhp160169
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose. The stability of 0.3-mg/mL tacrolimus ophthalmic solution at different storage temperatures was studied. Methods. A sterile ophthalmic solution of 0.3 mg/mL tacrolimus was prepared in triplicate under aseptic conditions by diluting tacrolimus in eye drops. Three aliquots of this solution were transferred into polypropylene bottles and stored at 25, 2-8, or -15 to -25 degrees C. Samples were collected immediately after preparation and at selected time points and assayed in triplicate using high-performance liquid chromatography (HPLC). Samples were also visually examined for macroscopic changes. The 0.3-mg/mL tacrolimus solution was also exposed to acidic treatment and heat to force its degradation and to evaluate the selectivity of the analytic method. The tacrolimus ophthalmic solution was considered stable if at least 90% of the mean initial concentration remained when analyzed by HPLC. Results. When stored at 2-8 degrees C and between -15 and -25 degrees C, at least 90% of the initial tacrolimus concentration remained throughout the 85-day study period. There were no significant differences in tacrolimus concentrations between the starting and ending points (p > 0.05). However, when tacrolimus solution was stored at 25 degrees C, the percentage of the initial tacrolimus concentration remaining had decreased to less than 90% on day 28. Conclusion. Tacrolimus diluted to 0.3 mg/mL in eye drop solution was stable for 20 days when stored at 25 degrees C and for at least 85 days when stored at 2-8 degrees C or between- 15 and -25 degrees C in polypropylene bottles and protected from light.
引用
收藏
页码:1002 / 1006
页数:5
相关论文
共 50 条
  • [21] Preclinical characterization and clinical evaluation of tacrolimus eye drops
    Luaces-Rodriguez, Andrea
    Tourino-Peralba, Rosario
    Alonso-Rodriguez, Iria
    Garcia-Otero, Xurxo
    Gonzalez-Barcia, Miguel
    Teresa Rodriguez-Ares, Maria
    Martinez-Perez, Laura
    Aguiar, Pablo
    Gomez-Lado, Noemi
    Silva-Rodriguez, Jesus
    Herranz, Michel
    Ruibal-Morell, Alvaro
    Jesus Lamas, Maria
    Otero-Espinar, Francisco J.
    Fernandez-Ferreiro, Anxo
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2018, 120 : 152 - 161
  • [22] Impacts of High Intra- and Inter-Individual Variability in Tacrolimus Pharmacokinetics and Fast Tacrolimus Metabolism on Outcomes of Solid Organ Transplant Recipients
    Thongprayoon, Charat
    Hansrivijit, Panupong
    Kovvuru, Karthik
    Kanduri, Swetha R.
    Bathini, Tarun
    Pivovarova, Aleksandra
    Smith, Justin R.
    Cheungpasitporn, Wisit
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (07)
  • [23] Tacrolimus therapy causes hepatotoxicity in patients with a history of liver disease
    Ko, Myong Suk
    Choi, Young Hee
    Jung, Sun Hoi
    Lee, Jenny Sue
    Kim, Hyang Sook
    Lee, Chang Ho
    Kim, Sang Geon
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2015, 53 (05) : 363 - 371
  • [24] Antiapoptotic Effect of Tacrolimus on Cytokine-Challenged Human Islets
    Balibrea del Castillo, Jose M.
    Cruz Garcia-Martin, M.
    Arias-Diaz, Javier
    Gine, Elena
    Vara, Elena
    Balibrea Cantero, Jose L.
    CELL TRANSPLANTATION, 2009, 18 (10-11) : 1237 - 1246
  • [25] Formulation development, optimization, and in vitro assessment of thermoresponsive ophthalmic pluronic F127-chitosan in situ tacrolimus gel
    Modi, Deepika
    Mohammad
    Warsi, Musarrat H.
    Garg, Vaidehi
    Bhatia, Meenakshi
    Kesharwani, Prashant
    Jain, Gaurav K.
    JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION, 2021, 32 (13) : 1678 - 1702
  • [26] Topical Tacrolimus Compared With Oral Tacrolimus for Postoperative Immunosuppression in Primary Keratolimbal Allograft
    Tran, Tu M.
    Azher, Tayaba N.
    Miller, Corey J.
    Hou, Joshua H.
    CORNEA, 2024, 43 (03) : 333 - 342
  • [27] Tacrolimus in transplant rejection
    Rath, Thomas
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (01) : 115 - 122
  • [28] Comparison of adverse drug reaction profiles of two tacrolimus formulations in rats
    Hwang, HyeonSeok
    Ghee, Jung Yeon
    Song, Ji Hyun
    Piao, ShangGuo
    Yang, Chul Woo
    IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 2012, 34 (03) : 434 - 442
  • [29] Characteristics of Patients with Dry Eye Who Switched from Long-Acting Ophthalmic Solution to Diquafosol Ophthalmic Solution
    Ishikawa, Sho
    Maruyama, Takafumi
    Murayama, Koichiro
    Shinoda, Kei
    JOURNAL OF CLINICAL MEDICINE, 2025, 14 (08)
  • [30] Tacrolimus as Antifungal Agent
    Antypenko, Lyudmyla
    Sadykova, Zhanar
    Meyer, Fatuma
    Garbe, Leif-Alexander
    Steffens, Karl
    ACTA CHIMICA SLOVENICA, 2019, 66 (04) : 784 - 791